交易中 02-17 15:05:10
0.000
0.00%
Northstrive Biosciences Inc. announces completion of Phase I research for its first-in-class oral myostatin-engineered probiotic, EL-22, targeting muscle-wasting conditions, including GLP-1-associated atrophy. Key findings include strong preclinical rationale and unique oral vaccine approach. The company plans Phase 2 trial for GLP-1 users and regulatory engagement for IND filing.
2025-05-22 12:16